novo nordisk eli lilly - Search News

News

Eli Lilly, Novo Nordisk latest battle in GLP-1 market war

Seeking Alpha on MSN · 1h

Eli Lilly, Novo Nordisk latest battle in GLP-1 market war: cash-paying customers

As Eli Lilly and Novo Nordisk have been battling it out to gain market share of the growing GLP-1 weight loss market, one demographic has been seen as increasingly important: cash-pay customers. These individuals,

Fox Business on MSN · 3h

Novo Nordisk to sell weight-loss drug for $499 to eligible customers

Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through multiple pharmacy platforms.

Yahoo Finance · 7h

Novo Nordisk, Eli Lilly, Soho House: Stocks

A closer look at today's Trending Tickers - the stocks making the biggest moves worldwide - including Eli Lilly (LLY), Novo Nordisk (NVO) and Soho House (SHCO).

3d

Novo Nordisk's Lead Fades, Eli Lilly Holds Course For Outsized Gains, Says Analyst

On Thursday, Eli Lilly and Co. (NYSE:LLY) said it will sharply increase the list price of its weight-loss and type 2 diabetes ...

2d

Eli Lilly Vs. Novo Nordisk: Correction Overly Done - GLP-1 Market Leadership/ Robust Pipelines Ahead

Novo Nordisk's (NVO) corrections amid AI market rotation might be an opportunity, due to GLP-1 market leadership & balanced ...

5h

Novo Nordisk stock soar 5% today: here’s why analysts are bullish

Novo Nordisk stock gains as FDA expands Wegovy use, while Ozempic price cut aims to boost access and defend market share.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results